These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24129240)

  • 1. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
    Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
    Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
    Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
    Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.
    Sonnemann J; Grauel D; Blümel L; Hentschel J; Marx C; Blumrich A; Focke K; Becker S; Wittig S; Schinkel S; Krämer OH; Beck JF
    Eur J Cancer; 2015 May; 51(7):841-51. PubMed ID: 25801700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
    Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
    Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.
    Hang W; Yin ZX; Liu G; Zeng Q; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Wang YS; Quan CS; Zhao RX; Li YL; Xu ZX
    Oncogene; 2018 Jun; 37(25):3384-3398. PubMed ID: 29348462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
    Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
    Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
    Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than
    Fujihara KM; Corrales Benitez M; Cabalag CS; Zhang BZ; Ko HS; Liu DS; Simpson KJ; Haupt Y; Lipton L; Haupt S; Phillips WA; Clemons NJ
    Mol Cancer Ther; 2021 Oct; 20(10):1858-1867. PubMed ID: 34315763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
    Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
    Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
    van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
    J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
    Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
    Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
    Kobayashi T; Makino T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Morii E; Eguchi H; Doki Y
    Br J Cancer; 2021 Nov; 125(11):1523-1532. PubMed ID: 34599296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.
    Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Strömblad S
    Cell Cycle; 2011 Jan; 10(2):301-7. PubMed ID: 21239882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
    Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
    Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
    Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
    Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.
    Roundhill EA; Chicon-Bosch M; Jeys L; Parry M; Rankin KS; Droop A; Burchill SA
    Cell Oncol (Dordr); 2021 Oct; 44(5):1065-1085. PubMed ID: 34403115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prima-1 and APR-246 in Cancer Therapy.
    Zatloukalová P; Galoczová M; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.